Treatment of Parkinsonism
Over the last decade the treatment of Parkinsonism has under gone major developments. Advances deriving from a logically structured series of laboratory experiments have been transferred to the clinic to generate substantial therapeutic achievements.
KeywordsDopamine Receptor Orthostatic Hypotension Dopamine Agonist Ergot Alkaloid Decarboxylase Inhibitor
Unable to display preview. Download preview PDF.
- Cools, A.R. and Van Rossum, J.M. (1975). Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharma- cologia (Berl). 45 ,243–254.CrossRefGoogle Scholar
- Jaton, A.L., Loew, D.M. and Vigouret, J.M. (1975). CF 25–397 (9,10 didehydro-6-methyl-8ß-[2-pyridylthiomethyl] ergoline), anew central dopamine receptor agonist. Proc B.P.S. 56 ,371.Google Scholar
- Kartzinel, R., Perlow, M.J., Carter, A.C., Chase, T.N. and Calne, D.B. (1976). Metabolic studies with bromocriptine in patients with idiopathic Parkinsonism and Huntington’s Chorea. Trans Am Neurol Assoc. In press.Google Scholar
- Lloyd, K.G., Davidson, L. and Hornykiewicz, O. (1973). Metabolism of levodopa in the human brain. In Advances in Neurology, Vol. 3, (Calne, D.B., Ed.) pp. 173–188. Raven Press, New York.Google Scholar
- Silbergeld, E.K., Adler, H., Kennedy, S. and Calne, D.B. (1976).Roles of presynaptic dopamine function and hepatic drug metabolism in effects of three dopamine agonists: bromocriptine, lergotrile and CF25-397. In press.Google Scholar
- Silbergeld, E.K. and Pfeiffer, R.F. (1976). Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile. In press.Google Scholar
- Teychenne, P.F., Jones, A. and Calne, D.B. (1976). Changes in liver function induced by lergotrile. In preparation.Google Scholar
- Teychenne, P.F., Pfeiffer, R.F. and Calne, D.B. (1976). Actions of CF25–397 in parkinsonism. In preparation.Google Scholar
- Yahr, M.D. (ed.) (1973). In Advances in Neurology, Vol. 2-Treatment of Parkinson’s Disease-the Use of Dopa Deoarboxylase Inhibitors. pp. 303. Raven Press, New York.Google Scholar